Wake Forest University Health Sciences, Center for Genomics and Personalized Medicine Research, Medical Center Boulevard, Winston-Salem, NC, United States.
Curr Opin Pharmacol. 2010 Jun;10(3):246-53. doi: 10.1016/j.coph.2010.04.009. Epub 2010 May 6.
The use of beta(2)-adrenergic receptor agonists, or beta agonists, and their potential for an increased risk of asthma-related death were identified in the 1960's, and appears to have been related to the marketing of specific preparations of short-acting beta agonists (SABA) that are no longer in use today. Subsequent studies have reported a potential for life-threatening or fatal adverse events with the use of long-acting beta agonist (LABA) therapy, but this conclusion must be tempered by the suboptimal design of the studies which form the foundation for these conclusions. Multiple prospective clinical trials and meta-analyses have demonstrated that the combination of a LABA and an ICS confers proven clinical benefits which appear greater than the rare risk for serious or life-threatening adverse events, although all of these studies have inadequate power to be definitive.
β2-肾上腺素受体激动剂（β受体激动剂）的使用及其可能增加哮喘相关死亡的风险，在 20 世纪 60 年代被发现，这似乎与特定短效β受体激动剂（SABA）制剂的营销有关，而这些制剂如今已不再使用。随后的研究报告称，长效β受体激动剂（LABA）治疗可能会导致危及生命或致命的不良事件，但这些结论必须根据构成这些结论基础的研究设计不佳进行调整。多项前瞻性临床试验和荟萃分析表明，LABA 和 ICS 的联合使用带来了已证实的临床获益，这些获益似乎大于罕见的严重或危及生命的不良事件风险，尽管所有这些研究都没有足够的效力来确定。
